Surging global prevalence of severe tricuspid regurgitation (TR) among aging patient populations, expanding clinical demand for less invasive alternatives to high-risk open-heart surgery, and continuous structural heart device innovations in transcatheter edge-to-edge repair (TEER) and replacement systems are driving rapid growth across the Tricuspid Valve Interventional Therapy Market....
